The record first. On August 27, 2024, Dexcom, Inc. was granted US12073075B2, "Wearable apparatus for continuous blood glucose monitoring" (CPC including A61B 5/14532 and G16H 50/30). Named inventors include Naresh C. Bhavaraju and Eric Cohen. The claim covers a wearable that continuously measures glucose — the proven, cleared, minimally-invasive approach that consumer non-invasive efforts are still chasing.
Follow the moat shape. Dexcom's franchise is not built on a sensor alone; it is built on regulatory clearance, clinical validation, physician relationships, and reimbursement integration. That stack is enormously expensive and slow to assemble, which is precisely why it is defensible. Each patent in the continuous-glucose portfolio reinforces a moat that consumer entrants cannot cheaply replicate.
The business framing is the contrast with consumer wearables. While consumer makers chase non-invasive glucose as a feature, the cleared, reimbursed market is already served by specialists whose advantage is the care-pathway integration, not just the sensor. A continuous-glucose grant from such a specialist is a marker of the moat's depth.
Comparability discipline applies. "Glucose monitoring" spans cleared continuous monitors (specialist, reimbursed) and aspirational non-invasive consumer features (unproven). The filing pins this claim to the cleared continuous approach — useful for understanding why the consumer threat is slower than the hype suggests, and easy to flatten under one label.
What the document does not disclose is the economics. It is a device claim, not a P&L. It will not tell you device revenue, reimbursement rates, or share. The grant reinforces a care-pathway position; the financials live in the company's filings, not the patent.
For investors, the throughline is this: the glucose franchise is protected by clearance and reimbursement, not just sensing, and the patent record shows how specialists deepen the moat consumer makers struggle to cross.